299 related articles for article (PubMed ID: 31768371)
1. Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.
Réus GZ; de Moura AB; Borba LA; Abelaira HM; Quevedo J
Mol Neuropsychiatry; 2019 Oct; 5(4):178-189. PubMed ID: 31768371
[TBL] [Abstract][Full Text] [Related]
2. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms.
Marcatili M; Sala C; Dakanalis A; Colmegna F; D'Agostino A; Gambini O; Dell'Osso B; Benatti B; Conti L; Clerici M
Ther Adv Psychopharmacol; 2020; 10():2045125320968331. PubMed ID: 33224469
[TBL] [Abstract][Full Text] [Related]
3. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Miller OH; Moran JT; Hall BJ
Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
[TBL] [Abstract][Full Text] [Related]
4. Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.
Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigström R; Jonsson L; Clements CC; Andersson E; Boberg J; Lewis CM; Sullivan PF; Landén M; Lu Y
Transl Psychiatry; 2023 Sep; 13(1):301. PubMed ID: 37770441
[TBL] [Abstract][Full Text] [Related]
5. Investigating genetic overlap between antidepressant and lithium response and treatment resistance in major depressive disorder.
Lu Y; Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigstrom R; Jonsson L; Clements C; Andersson E; Boberg J; Lewis C; Sullivan P; Landén M
Res Sq; 2023 Feb; ():. PubMed ID: 36865283
[TBL] [Abstract][Full Text] [Related]
6. [Treatment resistant depression: actuality and perspectives in 2017].
Lucas N; Hubain P; Loas G; Jurysta F
Rev Med Brux; 2017; 38(1):16-25. PubMed ID: 28525197
[TBL] [Abstract][Full Text] [Related]
7. Role of Ketamine in the Treatment of Psychiatric Disorders.
Derakhshanian S; Zhou M; Rath A; Barlow R; Bertrand S; DeGraw C; Lee C; Hasoon J; Kaye AD
Health Psychol Res; 2021; 9(1):25091. PubMed ID: 35106397
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology.
Alario AA; Niciu MJ
Chronic Stress (Thousand Oaks); 2021; 5():24705470211014210. PubMed ID: 34159281
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.
Vecera CM; C Courtes A; Jones G; Soares JC; Machado-Vieira R
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004437
[TBL] [Abstract][Full Text] [Related]
10. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
[TBL] [Abstract][Full Text] [Related]
11. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression.
Kim YK; Na KS
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():117-26. PubMed ID: 27046518
[TBL] [Abstract][Full Text] [Related]
12. The role of ketamine in treatment-resistant depression: a systematic review.
Serafini G; Howland RH; Rovedi F; Girardi P; Amore M
Curr Neuropharmacol; 2014 Sep; 12(5):444-61. PubMed ID: 25426012
[TBL] [Abstract][Full Text] [Related]
13. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
[TBL] [Abstract][Full Text] [Related]
14. Management of Treatment-Resistant Depression: Challenges and Strategies.
Voineskos D; Daskalakis ZJ; Blumberger DM
Neuropsychiatr Dis Treat; 2020; 16():221-234. PubMed ID: 32021216
[TBL] [Abstract][Full Text] [Related]
15. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
Ghasemi M; Kazemi MH; Yoosefi A; Ghasemi A; Paragomi P; Amini H; Afzali MH
Psychiatry Res; 2014 Feb; 215(2):355-61. PubMed ID: 24374115
[TBL] [Abstract][Full Text] [Related]
16. The medial forebrain bundle as a deep brain stimulation target for treatment resistant depression: A review of published data.
Gálvez JF; Keser Z; Mwangi B; Ghouse AA; Fenoy AJ; Schulz PE; Sanches M; Quevedo J; Selvaraj S; Gajwani P; Zunta-Soares G; Hasan KM; Soares JC
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():59-70. PubMed ID: 25530019
[TBL] [Abstract][Full Text] [Related]
17. Treatment resistant depression--advances in somatic therapies.
Kennedy SH; Giacobbe P
Ann Clin Psychiatry; 2007; 19(4):279-87. PubMed ID: 18058285
[TBL] [Abstract][Full Text] [Related]
18. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
